Intensity Therapeutics (INTS) Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shares of Intensity Therapeutics, Inc. (INTS) are up 142% on Friday after the company announced positive Phase 2 INVINCIBLE trial data of INT230-6 in patients with early-stage breast cancer without chemotherapy.
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a.
/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.
/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.